TIDMOPTI

RNS Number : 8356Q

OptiBiotix Health PLC

11 June 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Notice of AGM

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the Annual General Meeting will be held on 4 July 2018 at 11am at the offices of Walbrook PR, 4 Lombard St, London EC3V 9HD.

For further information, please contact:

 
 OptiBiotix Health plc                                               www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                   Contact via Walbrook 
                                                                                  below 
 
 Cairn Financial Advisers LLP (NOMAD)                                Tel: 020 7213 0880 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                                  Tel: 020 7220 0500 
 Adrian Hargrave / Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Abigail Wayne (Corporate Broking) 
 
 Walbrook PR Ltd                        Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                                         Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOAFPMITMBBMBMP

(END) Dow Jones Newswires

June 11, 2018 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Optibiotix Health Charts.